• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

葡萄糖和脂质代谢重编程在肾透明细胞癌原代培养物中呈分级依赖性,并且可通过靶向调节来影响细胞活力和增殖。

The glucose and lipid metabolism reprogramming is grade-dependent in clear cell renal cell carcinoma primary cultures and is targetable to modulate cell viability and proliferation.

作者信息

Bianchi Cristina, Meregalli Chiara, Bombelli Silvia, Di Stefano Vitalba, Salerno Francesco, Torsello Barbara, De Marco Sofia, Bovo Giorgio, Cifola Ingrid, Mangano Eleonora, Battaglia Cristina, Strada Guido, Lucarelli Giuseppe, Weiss Robert H, Perego Roberto A

机构信息

School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.

Pathology Unit, ASST Monza, San Gerardo Hospital, Monza, Italy.

出版信息

Oncotarget. 2017 Dec 8;8(69):113502-113515. doi: 10.18632/oncotarget.23056. eCollection 2017 Dec 26.

DOI:10.18632/oncotarget.23056
PMID:29371925
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5768342/
Abstract

Clear cell renal cell carcinoma (ccRCC) has a poor prognosis despite novel biological targeted therapies. Tumor aggressiveness and poor survival may correlate with tumor grade at diagnosis and with complex metabolic alterations, also involving glucose and lipid metabolism. However, currently no grade-specific metabolic therapy addresses these alterations. Here we used primary cell cultures from ccRCC of low- and high-grade to investigate the effect on energy state and reduced pyridine nucleotide level, and on viability and proliferation, of specific inhibition of glycolysis with 2-deoxy-D-glucose (2DG), or fatty acid oxidation with Etomoxir. Our primary cultures retained the tissue grade-dependent modulation of lipid and glycogen storage and aerobic glycolysis (Warburg effect). 2DG affected lactate production, energy state and reduced pyridine nucleotide level in high-grade ccRCC cultures, but the energy state only in low-grade. Rather, Etomoxir affected energy state in high-grade and reduced pyridine nucleotide level in low-grade cultures. Energy state and reduced pyridine nucleotide level were evaluated by ATP and reduced 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) dye quantification, respectively. 2DG treatment impaired cell proliferation and viability of low-grade ccRCC and normal cortex cultures, whereas Etomoxir showed a cytostatic and cytotoxic effect only in high-grade ccRCC cultures. Our data indicate that in ccRCC the Warburg effect is a grade-dependent feature, and fatty acid oxidation can be activated for different grade-dependent metabolic needs. A possible grade-dependent metabolic therapeutic approach in ccRCC is also highlighted.

摘要

尽管有新型生物靶向疗法,但透明细胞肾细胞癌(ccRCC)的预后仍然很差。肿瘤侵袭性和较差的生存率可能与诊断时的肿瘤分级以及复杂的代谢改变有关,这些改变还涉及葡萄糖和脂质代谢。然而,目前尚无针对这些改变的分级特异性代谢疗法。在此,我们使用来自低级别和高级别ccRCC的原代细胞培养物,研究用2-脱氧-D-葡萄糖(2DG)特异性抑制糖酵解或用依托莫昔抑制脂肪酸氧化对能量状态、吡啶核苷酸水平降低以及活力和增殖的影响。我们的原代培养物保留了脂质和糖原储存以及有氧糖酵解(瓦伯格效应)的组织分级依赖性调节。2DG影响高级别ccRCC培养物中的乳酸产生、能量状态和吡啶核苷酸水平降低,但仅影响低级别培养物中的能量状态。相反,依托莫昔影响高级别培养物中的能量状态,并降低低级别培养物中的吡啶核苷酸水平。能量状态和吡啶核苷酸水平降低分别通过ATP和还原型3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四氮唑(MTT)染料定量来评估。2DG处理损害了低级别ccRCC和正常皮质培养物的细胞增殖和活力,而依托莫昔仅在高级别ccRCC培养物中显示出细胞生长抑制和细胞毒性作用。我们的数据表明,在ccRCC中,瓦伯格效应是一种分级依赖性特征,脂肪酸氧化可因不同的分级依赖性代谢需求而被激活。还强调了ccRCC中一种可能的分级依赖性代谢治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5dd/5768342/fc61107237c2/oncotarget-08-113502-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5dd/5768342/394eef0d6fce/oncotarget-08-113502-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5dd/5768342/1abf1a065d5b/oncotarget-08-113502-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5dd/5768342/c06c0743008e/oncotarget-08-113502-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5dd/5768342/bece1c82b687/oncotarget-08-113502-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5dd/5768342/72461517d9ab/oncotarget-08-113502-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5dd/5768342/19446b820d8e/oncotarget-08-113502-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5dd/5768342/fc61107237c2/oncotarget-08-113502-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5dd/5768342/394eef0d6fce/oncotarget-08-113502-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5dd/5768342/1abf1a065d5b/oncotarget-08-113502-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5dd/5768342/c06c0743008e/oncotarget-08-113502-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5dd/5768342/bece1c82b687/oncotarget-08-113502-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5dd/5768342/72461517d9ab/oncotarget-08-113502-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5dd/5768342/19446b820d8e/oncotarget-08-113502-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5dd/5768342/fc61107237c2/oncotarget-08-113502-g007.jpg

相似文献

1
The glucose and lipid metabolism reprogramming is grade-dependent in clear cell renal cell carcinoma primary cultures and is targetable to modulate cell viability and proliferation.葡萄糖和脂质代谢重编程在肾透明细胞癌原代培养物中呈分级依赖性,并且可通过靶向调节来影响细胞活力和增殖。
Oncotarget. 2017 Dec 8;8(69):113502-113515. doi: 10.18632/oncotarget.23056. eCollection 2017 Dec 26.
2
The platelet isoform of phosphofructokinase contributes to metabolic reprogramming and maintains cell proliferation in clear cell renal cell carcinoma.磷酸果糖激酶的血小板亚型有助于代谢重编程并维持肾透明细胞癌中的细胞增殖。
Oncotarget. 2016 May 10;7(19):27142-57. doi: 10.18632/oncotarget.8382.
3
Metabolic reprogramming of clear cell renal cell carcinoma.透明细胞肾细胞癌的代谢重编程。
Front Endocrinol (Lausanne). 2023 Jun 6;14:1195500. doi: 10.3389/fendo.2023.1195500. eCollection 2023.
4
Efficient generation of patient-matched malignant and normal primary cell cultures from clear cell renal cell carcinoma patients: clinically relevant models for research and personalized medicine.从透明细胞肾细胞癌患者中高效生成患者匹配的恶性和正常原代细胞培养物:用于研究和个性化医疗的临床相关模型
BMC Cancer. 2016 Jul 16;16:485. doi: 10.1186/s12885-016-2539-z.
5
c-Myc modulates glucose metabolism via regulation of miR-184/PKM2 pathway in clear-cell renal cell carcinoma.c-Myc 通过调节 miR-184/PKM2 通路调控肾透明细胞癌的葡萄糖代谢。
Int J Oncol. 2016 Oct;49(4):1569-75. doi: 10.3892/ijo.2016.3622. Epub 2016 Jul 14.
6
Comparison of biexponential and monoexponential DWI in evaluation of Fuhrman grading of clear cell renal cell carcinoma.双指数和单指数扩散加权成像在评估透明细胞肾细胞癌Fuhrman分级中的比较
Diagn Interv Radiol. 2017 Mar-Apr;23(2):100-105. doi: 10.5152/dir.2016.15519.
7
Gene expression analysis in clear cell renal cell carcinoma using gene set enrichment analysis for biostatistical management.基于基因集富集分析的 clear cell 肾细胞癌基因表达分析用于生物统计学管理。
BJU Int. 2011 Jul;108(2 Pt 2):E29-35. doi: 10.1111/j.1464-410X.2010.09794.x. Epub 2011 Mar 16.
8
Multiparametric Magnetic Resonance Imaging and Metabolic Characterization of Patient-Derived Xenograft Models of Clear Cell Renal Cell Carcinoma.透明细胞肾细胞癌患者来源异种移植模型的多参数磁共振成像与代谢特征分析
Metabolites. 2022 Nov 15;12(11):1117. doi: 10.3390/metabo12111117.
9
Reduced expression of growth and differentiation factor-9 (GDF9) is associated with aggressive behaviour of human clear-cell renal cell carcinoma and poor patient survival.生长分化因子9(GDF9)表达降低与人类透明细胞肾细胞癌的侵袭性行为及患者较差的生存率相关。
Anticancer Res. 2014 Nov;34(11):6515-20.
10
hZIP1 that is down-regulated in clear cell renal cell carcinoma is negatively associated with the malignant potential of the tumor.在透明细胞肾细胞癌中表达下调的hZIP1与肿瘤的恶性潜能呈负相关。
Urol Oncol. 2014 Aug;32(6):885-92. doi: 10.1016/j.urolonc.2014.02.021. Epub 2014 May 28.

引用本文的文献

1
Metabolic landscape of clear cell renal cell carcinoma and search for metabolites predictive of drug response.透明细胞肾细胞癌的代谢图谱及预测药物反应的代谢物研究
BMC Cancer. 2025 Aug 22;25(1):1357. doi: 10.1186/s12885-025-14661-4.
2
Diagnosis and management of TFE3-rearranged renal cell carcinoma: case report and literature review.TFE3 重排肾细胞癌的诊断与管理:病例报告及文献综述
BMC Urol. 2025 Aug 20;25(1):207. doi: 10.1186/s12894-025-01908-2.
3
GFOD1 expression in clear cell renal cell carcinoma and its role in cancer cell proliferation, migration, and invasion.

本文引用的文献

1
Glutamine Addiction in Kidney Cancer Suppresses Oxidative Stress and Can Be Exploited for Real-Time Imaging.肾癌中的谷氨酰胺成瘾抑制氧化应激并可用于实时成像。
Cancer Res. 2017 Dec 1;77(23):6746-6758. doi: 10.1158/0008-5472.CAN-17-0930. Epub 2017 Oct 11.
2
Evaluation of renal cell carcinoma histological subtype and fuhrman grade using F-fluorodeoxyglucose-positron emission tomography/computed tomography.利用 F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描评估肾细胞癌的组织学亚型和 Fuhrman 分级。
Eur Radiol. 2017 Nov;27(11):4866-4873. doi: 10.1007/s00330-017-4875-z. Epub 2017 May 18.
3
Metabolic reprogramming in clear cell renal cell carcinoma.
GFOD1在透明细胞肾细胞癌中的表达及其在癌细胞增殖、迁移和侵袭中的作用。
Discov Oncol. 2025 Jul 1;16(1):1212. doi: 10.1007/s12672-025-03049-2.
4
Identification of CENPW as a prognostic biomarker and potential therapeutic target for clear cell renal cell carcinoma.鉴定CENPW作为透明细胞肾细胞癌的预后生物标志物和潜在治疗靶点。
Discov Oncol. 2025 Jun 18;16(1):1138. doi: 10.1007/s12672-025-02859-8.
5
Analysis of immune status and prognostic model incorporating lactate metabolism and immune-related genes in clear cell renal cell carcinoma.透明细胞肾细胞癌中免疫状态分析及结合乳酸代谢和免疫相关基因的预后模型
Discov Oncol. 2025 Jun 7;16(1):1024. doi: 10.1007/s12672-025-02746-2.
6
The Metabolic Landscape of Cancer Stem Cells: Insights and Implications for Therapy.癌症干细胞的代谢格局:对治疗的见解与启示
Cells. 2025 May 15;14(10):717. doi: 10.3390/cells14100717.
7
Role of fructose in renal cell carcinoma progression.果糖在肾细胞癌进展中的作用。
Discov Oncol. 2025 May 23;16(1):897. doi: 10.1007/s12672-025-02688-9.
8
Proteomics and succinylation modification characterization in clear cell renal cell carcinoma.透明细胞肾细胞癌中的蛋白质组学与琥珀酰化修饰特征分析
Discov Oncol. 2025 May 20;16(1):835. doi: 10.1007/s12672-025-02737-3.
9
LPCAT3 regulates the immune infiltration and prognosis of ccRCC patients by mediating ferroptosis and endoplasmic reticulum stress.LPCAT3通过介导铁死亡和内质网应激来调节ccRCC患者的免疫浸润和预后。
Discov Oncol. 2025 Apr 19;16(1):574. doi: 10.1007/s12672-025-02283-y.
10
The pathogenesis and therapeutic implications of metabolic reprogramming in renal cell carcinoma.肾细胞癌中代谢重编程的发病机制及治疗意义
Cell Death Discov. 2025 Apr 19;11(1):186. doi: 10.1038/s41420-025-02479-9.
透明细胞肾细胞癌中的代谢重编程。
Nat Rev Nephrol. 2017 Jul;13(7):410-419. doi: 10.1038/nrneph.2017.59. Epub 2017 May 8.
4
Renal cell carcinoma.肾细胞癌。
Nat Rev Dis Primers. 2017 Mar 9;3:17009. doi: 10.1038/nrdp.2017.9.
5
Renal-cell carcinoma in 2016: Advances in treatment - jostling for pole position.2016年肾细胞癌:治疗进展——争夺领先地位。
Nat Rev Clin Oncol. 2017 Feb;14(2):82-84. doi: 10.1038/nrclinonc.2016.224. Epub 2017 Jan 10.
6
Major Action of Endogenous Lysyl Oxidase in Clear Cell Renal Cell Carcinoma Progression and Collagen Stiffness Revealed by Primary Cell Cultures.内源性赖氨酰氧化酶在透明细胞肾细胞癌进展和胶原硬度中的主要作用,通过原代细胞培养揭示。
Am J Pathol. 2016 Sep;186(9):2473-85. doi: 10.1016/j.ajpath.2016.05.019. Epub 2016 Jul 19.
7
Novel drugs that target the metabolic reprogramming in renal cell cancer.靶向肾细胞癌代谢重编程的新型药物。
Cancer Metab. 2016 Jul 13;4:14. doi: 10.1186/s40170-016-0154-8. eCollection 2016.
8
Proteotranscriptomic Analysis Reveals Stage Specific Changes in the Molecular Landscape of Clear-Cell Renal Cell Carcinoma.蛋白质转录组学分析揭示了透明细胞肾细胞癌分子格局的阶段特异性变化。
PLoS One. 2016 Apr 29;11(4):e0154074. doi: 10.1371/journal.pone.0154074. eCollection 2016.
9
A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review.酪氨酸激酶抑制剂治疗转移性肾细胞癌的十年药物基因组学研究:系统评价。
Expert Rev Mol Diagn. 2016;16(5):605-18. doi: 10.1586/14737159.2016.1148601. Epub 2016 Feb 17.
10
An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma.透明细胞肾细胞癌的综合代谢图谱
Cancer Cell. 2016 Jan 11;29(1):104-116. doi: 10.1016/j.ccell.2015.12.004.